Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Qiagen NV (GB:0RLT)
LSE:0RLT
Qiagen (0RLT) Share Price & Analysis
0 Followers
0RLT Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€31.82 - €48.18
Previous Close€38.9
Volume127.38K
Average Volume (3M)232.34K
Market Cap
€8.66B
Enterprise Value€9.10B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$1.53B
Price to Earnings (P/E)27.5
Beta0.40
Next Earnings
Apr 29, 2024EPS Estimate
€0.41Last Dividend Ex-Date
Jan 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)1.41
Shares Outstanding228,202,755
10 Day Avg. Volume310,950
30 Day Avg. Volume232,335
Standard Deviation0.09
R-Squared0.00018
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)11.87
Price to Sales (P/S)4.85
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.97
Enterprise Value/Gross Profit7.38
Enterprise Value/Ebitda26.62
Forecast
1Y Price Target
€48.79Price Target Upside25.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Qiagen News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQGEN reported results that exceeded expectations with robust non-COVID growth, demonstrating its ability to outperform peers.
Product PerformanceQuantiFERON and new products like QIAcuity and QIAStat are seeing significant growth and market adoption, signaling a strong product lineup.
Valuation And Growth PotentialQGEN's stock presents a valuation upside due to its current discount compared to historical averages, combined with a conservative revenue guide suggesting potential for growth outperformance.
Bears Say
Earnings GuidanceAlthough initial 2024 revenue and EPS guidance came in slightly below consensus, analysts sense some conservatism.
Regional SalesAmericas grew +6% non-COVID CER, while EMEA grew -1% non-COVID CER and APAC sales were -8% non-COVID CER.
Stock PerformanceQGEN shares have seen multiple compression and have underperformed peers.
---
0RLT FAQ
What was Qiagen NV’s price range in the past 12 months?
Qiagen NV lowest share price was €31.82 and its highest was €48.18 in the past 12 months.
What is Qiagen NV’s market cap?
Currently, no data Available
When is Qiagen NV’s upcoming earnings report date?
Qiagen NV’s upcoming earnings report date is Apr 29, 2024 which is in 4 days.
How were Qiagen NV’s earnings last quarter?
Qiagen NV released its earnings results on Feb 06, 2024. The company reported €0.516 earnings per share for the quarter, missing the consensus estimate of €0.517 by >-€0.001.
Is Qiagen NV overvalued?
According to Wall Street analysts Qiagen NV’s price is currently Undervalued.
Does Qiagen NV pay dividends?
Qiagen NV pays a Notavailable dividend of €1.2 which represents an annual dividend yield of N/A. See more information on Qiagen NV dividends here
What is Qiagen NV’s EPS estimate?
Qiagen NV’s EPS estimate is €0.41.
How many shares outstanding does Qiagen NV have?
Qiagen NV has 221,356,630 shares outstanding.
What happened to Qiagen NV’s price movement after its last earnings report?
Qiagen NV reported an EPS of €0.516 in its last earnings report, missing expectations of €0.517. Following the earnings report the stock price went down -3.998%.
Which hedge fund is a major shareholder of Qiagen NV?
Among the largest hedge funds holding Qiagen NV’s share is Woodline Partners LP. It holds Qiagen NV’s shares valued at 15M.
---
Qiagen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€48.79 (25.98% Upside)
€48.79 (25.98% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.87%
12-Months-Change
Fundamentals
Return on Equity
9.38%
Trailing 12-Months
Asset Growth
-2.74%
Trailing 12-Months
Company Description
Qiagen NV
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
---
0RLT Company Deck
---
0RLT Earnings Call
Q4 2024
0:00 / 0:00
---
0RLT Stock 12 Months Forecast
Average Price Target
€48.79
▲(25.98% Upside)
Technical Analysis
Best Analysts Covering 0RLT
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-0.28%
reiterated a buy rating 3 months ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -0.28% per trade.
---